Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
RCT (n=623) showed that high-dose, pharmaceutical-grade biotin (MD1003) did not significantly improve disability or walking speed vs placebo (12% vs 9%; OR 1.35; 95% CI 0.81–2.26) and due to potential for interference of laboratory tests, cannot be recommended.
Source:
Journal of Clinical Oncology
SPS commentary:
Biotin is a cofactor for several carboxylases that are involved in key neurometabolic pathways, including energy production and myelin synthesis.High-dose Pharmaceutical grade Biotin (MD1003) is being investigated as a treatment in progressive multiple sclerosis, a phase of the disease that is accompanied by metabolic perturbations and neurodegeneration, including degeneration of the corticospinal motor pathway.